Cancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation
Gabriel de Camargo Zaccariotto, Maria Julia Bistaffa, Angelica Maria Mazuera Zapata, Camila Fernanda Rodero, Fernanda Coelho, João Victor Brandão Quitiba, Lorena Letícia Peixoto de Lima, Raquel González Sterman, Valéria Maria de Oliveira Cardoso, Valtencir Zucolotto
Abstract
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.